9.13
Schlusskurs vom Vortag:
$8.62
Offen:
$8.56
24-Stunden-Volumen:
304.44K
Relative Volume:
1.31
Marktkapitalisierung:
$432.88M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-9.9239
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
+4.58%
1M Leistung:
-2.77%
6M Leistung:
+5.43%
1J Leistung:
-2.25%
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TBPH
Theravance Biopharma Inc
|
9.13 | 432.88M | 62.02M | -45.65M | -9.60M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-04-12 | Eingeleitet | BTIG Research | Buy |
2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-07-07 | Eingeleitet | JP Morgan | Overweight |
2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
2020-05-13 | Eingeleitet | Cowen | Outperform |
2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-05-11 | Bestätigt | Needham | Buy |
2016-12-21 | Eingeleitet | Needham | Buy |
2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2016-06-20 | Eingeleitet | Guggenheim | Buy |
2016-06-20 | Bestätigt | Leerink Partners | Outperform |
2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World
(TBPH) Trading Signals - news.stocktradersdaily.com
Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire
Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal
Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire
Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World
Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha
Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire
Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter
What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World
Where are the Opportunities in (TBPH) - news.stocktradersdaily.com
Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks
Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World
Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat
Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey
FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
What is HC Wainwright’s Estimate for TBPH FY2028 Earnings? - Defense World
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Theravance Biopharma Reports Record 2024 Financial Results - TipRanks
Theravance Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Theravance Biopharma Inc Reports Q4 2024 Earnings: YUPELRI Sales - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result - Yahoo Finance
Theravance Biopharma: Strategic Milestones and Revenue Forecasts Justify Buy Rating - TipRanks
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):